日本呼吸器学会雑誌第45巻第2号

Size: px
Start display at page:

Download "日本呼吸器学会雑誌第45巻第2号"

Transcription

1

2 ADL: Feeding Transfer Dressing Bathing IADL: Shopping Transportation Table1 Spector-KatzIndex * ADL-IADLisevaluatedbythesum ofeachscore(0:totaly dependent,6:totalyindependent) Table2 Generalcharacteristicsofthepatients Age(years) Male/Female Height(cm) BMI MRCscale BDIfocalscore GOLD stage PaO2 (Torr) PaCO2 (Torr) VC (ml) VC (% predicted) FEV1 (ml) FEV1 (% predicted) FEV1/FVC (%) 6MWD (m) ΔSpO2(%) Borgscaleafterthe6-minutewalk COPD (n=111) 70± 7 104:7 161± ± ,2-23,3-40,4-40, ± 1.9 I-2,I-21, I-45,IV ± 11.1 *26caseswerebreathingoxygen. 43.7± 7.4 2,580± ± ± ± ± ± ± ± 2.0 non-copd (n=93) 69± 6 69:24 159± ± ,2-15,3-34, ± ± 10.8 *34caseswerebreathingoxygen. 47.0± 8.4 1,740± ± ,080± ± ± ± ± ± 2.2 BMI:bodymassindex,BDI:BaselineDyspneaIndex,VC:vitalcapacity,FEV1:forcedexpiratoryvolumein1second, FVC:forcedvitalcapacity,6MWD:6-minutewalkingdistance,Δ SpO2:oxygendesaturationduringthe6-minutewalk.

3 Fig.1 ADL-IADLscore A:COPD group,b:non-copd group

4 Table3 Accuracyindeterminingthelevelthreerespiratoryhandicapsusingthecurrentcriteria A.A lcases B.COPD C.non-COPD D.Interstitiallungdisease Fig.2 SimplelogisticregressioncurvesshowingtherelationbetweenADL-IADLscoreandFEV1Index (A),and6-minutewalkingdistance(B)inpatientswithCOPD. TheY-axisindicatestheprobabilityofanADL-IADLscoreof4orless.Whenthe6-minutewalkingdistanceis270m,theprobabilityofanADL-IADLscoreof4orlessis50%.

5 Fig.3 Cross-tableanalysesbetweenADL-IADLscoreandGOLD stage(a),supplementaloxygenuse(b), andmrcscale(c)inpatientswithcopd.

6 Table4 MultivariatelogisticregressionmodelestimatinginpatientswithCOPD from thethreeselectedparameters Estimation SD χ 2 p 95% CI, upperlimitlowerlimit Oddsratio Intercept MRCgrade(1-3/4,5) MWD (270m) Supplementaloxygen(+ /-) < p< ,R 2 =0.341 Abbreviationsareshownintable1. Fig.4 SimplelogisticcurvesshowingtherelationbetweenADL-IADLscoreandFEV1index(A),and6- minutewalkingdistance(b)in patientswithnon-copd lungdisease. Y-axisindicatestheprobabilityofanADL-IADLscoreof4orless.When6-minutewalkingdistanceis255 m,theprobabilityofadl-iadlscoreof4orlessis50%. Fig.5 Cross-tableanalysesbetweenADL-IADLscoreandsupplementaloxygenuse(A),andMRCscale (B)inpatientswithnon-COPD lungdisease.

7 Table5 Multivariatelogisticregressionmodelestimatinginpatientswithnon-COPD lungdiseasefrom thethreeselectedparameters Estimation SD χ 2 p 95% CI, upperlimit lowerlimit Oddsratio Intercept MRCgrade(1-3/4,5) MWD (255m) Supplementaloxygen(+ /-) p< ,R 2 =0.328 Fig.6 SimplelogisticcurvesshowingtherelationbetweenADL-IADLscoreandFEV1Index(A),and6- minutewalkingdistance(b)inpatientswithinterstitiallungdisease. TheY-axisindicatestheprobabilityofanADL-IADLscoreof4orless.When6-minutewalkingdistance is280m,theprobabilityofanadl-iadlscoreof4orlessis50%. Fig.7 ROCcurves,FEV1Index(A)and6-minutewalkingdistance(B)

8 Table6 Accuracyindeterminingthelevelthreerespiratoryhandicapusingthenew criteria A.A lcases B.COPD C.non-COPD D.Interstitiallungdisease Table7 Predictiveabilityofthecurrentandnew criteriaforadl Sensitivity Specificity PPV NPV Overalaccuracy A lcases currentcriteria new criteria COPD currentcriteria new criteria Non-COPD currentcriteria new criteria Interstitiallungdisease currentcriteria new criteria PPV:positivepredictivevalue,NPV:negativepredictivevalue

9

10

11

01-30

01-30 COPD 3 4 4 5 5 6 6 8 8 10 10 11 11 11 12 12 12 12 19 19 20 20 21 21 21 23 23 24 24 25 25 25 26 26 26 27 4 8 13 28 13 13 14 16 16 p10 p16 p5 p6 p23 p20 p32 p33 p33 p35 p41 p41 p37 p47 p51 p70 p54 p59 p62

More information

橡stat3.PDF

橡stat3.PDF 1 2 3 4 5 T + D T nod T + nod D T D T + nod T + D D + nod T + T + + T a a + c d b + d b b + d = 1 specificity c a + c = 1 sensitivity a a + b d c + d a + c a + b + c + d a + b a + b + c + d a + d a + b

More information

1 FEV1.0 FEV1.0 30 80% NIH FEV1.0 50 80% FEV1.0 50% FEV1.0 cyanosis PaO2 PaCO2 PaO2 PaCO2 40mmHg FEV1.0 25% 2 1 1 2

1 FEV1.0 FEV1.0 30 80% NIH FEV1.0 50 80% FEV1.0 50% FEV1.0 cyanosis PaO2 PaCO2 PaO2 PaCO2 40mmHg FEV1.0 25% 2 1 1 2 15 1 12 1 2 2 2 2.1.............................. 3 2.2........................... 3 2.3 β........................ 6 2.4............................ 7 3 8 3.1....................... 8 3.2....................

More information

- 1 - 15 2030 4 21 21-2 - 2 1 21 21 4 22 31 10 5 26 ( JA ) - 3 - 4 21 7 9 9 34 1,386 1,003 94 58 1,155 60 25 33 1 3 2-4 - 12 17 60 7 7 12 H1217 4 7 30 34 19-5 - - 6 - (BMI*18.5) 20 15.2%30 8.% 20 86.4%30

More information

【知事入れ版】270804_鳥取県人口ビジョン素案

【知事入れ版】270804_鳥取県人口ビジョン素案 7 6 5 4 3 2 1 65 1564 14 192 193 194 195 196 197 198 199 2 21 22 23 24 1.65 1,4 1.6 1,2 1.55 1, 1.45 6 1.5 8 1.4 4 1.35 1.3 2 27 28 29 21 211 212 213 214 6 5 4 3 2 1 213 218 223 228 233 238 243 248 253

More information

Microsoft Word - aphj_slides pptx

Microsoft Word - aphj_slides pptx 1 99.2 10 98.5 10 15 95 20 2 24 U1RNP 140 90 3 100 20 25 4 5 WHO 6 10 20 10 10 15 7 10 1990 2000 2009 WHO 20 1990 8 11 0.002 10 10 20 10 12 9 13 MCTD 10 20 60 10 14 10 40 / 11 15 16 %VC FEV 1 COPD DLCO

More information

untitled

untitled -- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

More information

untitled

untitled NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

More information

抜管基準(翻訳)

抜管基準(翻訳) Criteria for Extubation and Tracheostomy Tube Removal For Patients With Ventilatory Failure CHEST 1996 110:1566-71 John R. Bach,MD,FCCP; Lou R,Saporito,RRT,BS 49 62 34 24 intermittent positive pressure

More information

! ! ! a b SIMV 12/min 0 (cmh 2O) 500.0 P/F (cmh 20) 8 0 (cmh 20) 6 400.0 300.0 200.0 100.0 (cmh 2O) 200 180 160 140 120 100 80 60 40 20 0 PS in 2043 2257 2115 2723 3022 3400

More information

エンジョイ北スポーツ

エンジョイ北スポーツ 2772083130 83 1 2 3 4 5 6 7 8 2 2 2 3 3 4 4 6 7 8 1211 53 /15,171 /509 /670 /13,992 2 83130 http://www.kita-city-taikyo.or.jp 83130 http://www.kita-city-taikyo.or.jp 3 68 35 45 4 83130 http://www.kita-city-taikyo.or.jp

More information

エンジョイ北スポーツ

エンジョイ北スポーツ 2672080127 3 1 2 3 2 3 4 4 5 5 5 7 8 4 5 6 7 8 1411 55/14,817 /259/655/13,903 2 80127 http://www.kita-city-taikyo.or.jp TOKYO TOKYO 80127 http://www.kita-city-taikyo.or.jp 3 4 80127 http://www.kita-city-taikyo.or.jp

More information

障害者職域拡大カリキュラム研究会中間報告書構成案

障害者職域拡大カリキュラム研究会中間報告書構成案 3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16

More information

2011 31th近畿学術集会 抄録

2011 31th近畿学術集会 抄録 2 1 2 3 9:25-9:30 9:30-10:30 1,2) 1,2,3) 1)2)3) 1,2) 1,2,3) 1)2)3) 1,2,3) 1,2) 1)2)3) 10:30-10:40 10:40-11:50 1) 1) 1) 2) 1) 1) 1) 2) 1) 2) 1) 2) 1) 2) 4 1) 2) 2) 1) 2) 1) 1) 1) 1) 2) 1) 2) 11:50-13:10

More information

終末期の呼吸困難症状への対応*松坂最終修正

終末期の呼吸困難症状への対応*松坂最終修正 Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,

More information

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1 11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1

More information

CF 2 CF CF 18 2 CF 1 1 CF CF CF

CF 2 CF CF 18 2 CF 1 1 CF CF CF 2 40 38 39 42 45 60 22 34 3 3 80 70 153 150 100 100 42 37 42 42 283 288 283 288 1,025 714 311 313 5 2 2 5 5 5 0 0 0 12 8 2 CF 2 CF CF 18 2 CF 1 1 CF CF 0 8 5 8 2 5 5 12 15 10 3 2 9 2 5 0 12 0 CF 3 5 5

More information

エンジョイ北スポーツ

エンジョイ北スポーツ 2881086133 http://www.kita-city-taikyo.or.jp 86 5 5 5 6 1 2 3 4 5 6 7 8 1915 54 /15,166 /568 /688 /13,910 2 86133 http://www.kita-city-taikyo.or.jp NTC 86133 http://www.kita-city-taikyo.or.jp 3 4 86133

More information

16 23 270 5 1 2 3 1 2 3 1 2 3 6 5 54 44 9 9 4,000 118 7 5 JA 8 1 1 2 16 48,000 1 1 1 1 2 2 3 1, 312. 87 4 5 10 3 31 6 10 4 25 7 3 1 2 8 2 495. 84 1 296. 49 2 199. 35 1 124. 62 54. 50 28. 80 34. 17 54.

More information

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8... 取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -

More information

1 2

1 2 ( ) ( ) ( ) 1 2 59 2 21 24 275 43 3 26 486 103 27 28 98 105 104 99 1 48 25 29 72 14 33 11-10 3 11 8 14,663 4 8 1 6.0 8 1 0.7 11-6 27 19 22 71 5 12 22 12 1,356 6 4,397 3 4 11 8 9 5 10 27 17 6 12 22 9

More information

P.5 P.6 P.3 P.4 P.7 P.8 P.9 P.11 P.19

P.5 P.6 P.3 P.4 P.7 P.8 P.9 P.11 P.19 MOST is the best! P.5 P.6 P.3 P.4 P.7 P.8 P.9 P.11 P.19 P.14 1 2 P.14 1 2 12,036 17,025 P.14 3 P.14 4 NEW P.12P.14 5 P.12P.14 6 P.12 P.15 7 NEW P.15 8 P.15 9 P.15 7 P.15 10 P.15 10 NEW P.12 P.15 11 P.15

More information

(1)〜(4)/松尾

(1)〜(4)/松尾 kcalkcal SV SV SV BMI BMI SV SV SV kcal kcal kcal kcal SV SV kcal SV SV SV SVSV SV SV SV SVSV SV SV SV SV SV SV SV SV SV SV SV SV SV SV BMI BMI BMI BMI (ADL kcal SV SV SV SV SV BMI kcal kcal BMI

More information

NSIPとUCTD(HP用).ppt

NSIPとUCTD(HP用).ppt NSIP (- NSIP) (Non-) NSIP (Kinder) Retrospective () (Non-) (Kinder) 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 1. 2. RA 3. Scl-70 4. SS-ASS-B 5. Jo-1 6. (>), CRP NSIP 62 6PM/DM* 9 47 *PM/DM: Polymyositis/dermatomyositis

More information

I II III IV V

I II III IV V I II III IV V N/m 2 640 980 50 200 290 440 2m 50 4m 100 100 150 200 290 390 590 150 340 4m 6m 8m 100 170 250 µ = E FRVβ β N/mm 2 N/mm 2 1.1 F c t.1 3 1 1.1 1.1 2 2 2 2 F F b F s F c F t F b F s 3 3 3

More information

3 ( 9 ) ( 13 ) ( ) 4 ( ) (3379 ) ( ) 2 ( ) 5 33 ( 3 ) ( ) 6 10 () 7 ( 4 ) ( ) ( ) 8 3() 2 ( ) 9 81

3 ( 9 ) ( 13 ) ( ) 4 ( ) (3379 ) ( ) 2 ( ) 5 33 ( 3 ) ( ) 6 10 () 7 ( 4 ) ( ) ( ) 8 3() 2 ( ) 9 81 1 ( 1 8 ) 2 ( 9 23 ) 3 ( 24 32 ) 4 ( 33 35 ) 1 9 3 28 3 () 1 (25201 ) 421 5 ()45 (25338 )(2540 )(1230 ) (89 ) () 2 () 3 ( ) 2 ( 1 ) 3 ( 2 ) 4 3 ( 9 ) ( 13 ) ( ) 4 ( 43100 ) (3379 ) ( ) 2 ( ) 5 33 ( 3 )

More information

A A OT 2 A OT A OT A A OT 4 OT A A OT A OT A OT A 3 OT 1 2 OT 2 2 1 2014105 26.5.12 26.5.27 26.6.4 26.9/116 OTPT 10/101 26.9.292 26.6/26 26.5/2727.5/31 2/ 2/ H26.10.177 26.10.21 22 27.2 27.3 27.4.1 27.4.21

More information

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

More information

【資料4】「健康な食事」資料集

【資料4】「健康な食事」資料集 資料 4 日本人の長寿を支える 健康な食事 のあり方に関する検討会 H25.6.24 24 21 60 65 70 75 80 85 90 70.42 73.62 79.55 86.30 34 22 22 (22 ) 1 65 38.8 24.2 (2012) 12.1 2 10 2522 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 15.1 6.1 3.5

More information

「東京都子供・子育て支援総合計画」中間見直し版(案)第2章 子供と家庭をめぐる状況

「東京都子供・子育て支援総合計画」中間見直し版(案)第2章 子供と家庭をめぐる状況 1 (1) (2) (3) (4) (5) (6) (7) (8) 2 (1) (2) (3) (4) (5) (6) (7) 10,000 100% 8,000 78.7% 78.1% 79.3% 78.3% 74.1% 75.4% 73.2% 80% 6,000 46.6% 47.5% 50.9% 51.5% 49.9% 51.8% 52.2% 60% 4,000 2,000 3,713

More information

272 日本呼吸ケア リハビリテーション学会誌第 22 巻第 3 号 表 1 Variables Value Age, yr Sex Male 81 Female 12 Height, cm Body weight, kg 6

272 日本呼吸ケア リハビリテーション学会誌第 22 巻第 3 号 表 1 Variables Value Age, yr Sex Male 81 Female 12 Height, cm Body weight, kg 6 2012 年 12 月 271 第 22 回日本呼吸ケア リハビリテーション学会学術集会 ( 福井 ) 奨励賞 受賞報告 特発性肺線維症における呼吸困難感, 運動 耐容能,QOL を含む多面的評価の重要性 要旨 IPF QOL IPF modified MRC modified MRC 6 SpO 2 modified MRC IPF IPF 6 QOL IPF QOL は じ め に 24 11

More information

2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 1, 2 1, 3? , 2 2, 3? k, l m, n k, l m, n kn > ml...? 2 m, n n m

2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 1, 2 1, 3? , 2 2, 3? k, l m, n k, l m, n kn > ml...? 2 m, n n m 2009 IA I 22, 23, 24, 25, 26, 27 4 21 1 1 2 1! 4, 5 1? 50 1 2 1 1 2 1 4 2 2 2 1?? 2 1 1, 2 1, 2 1, 2, 3,... 1, 2 1, 3? 2 1 3 1 2 1 1, 2 2, 3? 2 1 3 2 3 2 k, l m, n k, l m, n kn > ml...? 2 m, n n m 3 2

More information

‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01

‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01 2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation

More information

表1票4.qx4

表1票4.qx4 iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614

More information

VISPO_06/01„”“ƒŁ\1-4

VISPO_06/01„”“ƒŁ\1-4 2006 Café vega Café vega 1. Café vega 2. 3. 4. 5. Café vega 2 3 c 4 5 1 6 7 8 9 10 11 12 13 14 15 16 17 18 3 5 7 3 5 9 00 10 00 A45 5 9 50 10 50 B35 10 10 30 11 30 C35 10 12 00 13 00 1,500 18210 18 19

More information

2 / 7

2 / 7 1 / 7 1.30 1.301.00m 2.00 2.001.00m 1.70 1.701.00m 2.4 2.41.0m 2.0 2.01.0m 1.08 1.20.9m 1.08 1.20.9m 2.5 2.51.0m 2.5 2.51.0m 0.9 1.00.9m 1.44 1.60.9m 2 / 7 ml ml 3 / 7 4 / 7 ) 5 / 7 6 / 7 0798-56-1710

More information

日本呼吸器学会雑誌第44巻第10号

日本呼吸器学会雑誌第44巻第10号 β Table1 Laboratoryfindingsonthefirstvisit Hematology WBC Neut. Lyn. Mon. Eos. Bas. RBC Hb Ht Plate 5,650 /μl 79.2 % 14.9 % 3.9 % 1.8 % 0.2 % 418 10 4 /μl 12.5g/dl 38.4 % 21.2 10 4 /μl Serology CRP IgG

More information

SD-6

SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 ⅡⅡ / / SD-6 SD-6 SD-6 SD-6 SD-6 / SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 / SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6 SD-6

More information

日本呼吸器学会雑誌第44巻第7号

日本呼吸器学会雑誌第44巻第7号 Table1Laboratoryfindingsonadmission Hematology Serology LungFunctionTest WBC 7,410 /μl CRP 7.7mg/dl VC 3.12L(97.2%) Neut 66.4 % KL-6 777U/ml FEV1.0 2.35L(78.25%) Eosino 3.2 % PT (INR) 0.94 %DLCO 47.6 %

More information

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2 (1) (2) SCI 2 SCI 2 24 2 12 2 2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

More information

スライド 1

スライド 1 Wilhelm Conrad Röntgen Mr. and Mrs. Röntgen s hands (1895) X 1895 11 8 CT 0.6 500 CT NPO 0.8 /1 CT MDCT 4 1998 0.35 /1 8 16 64 2004 Takayasu CAD+PAD CT CT Angiography CTA SG Adamkiewicz PCI CABG CTA plaque

More information

「諸雑公文書」整理の中間報告

「諸雑公文書」整理の中間報告 30 10 3 from to 10 from to ( ) ( ) 20 20 20 20 20 35 8 39 11 41 10 41 9 41 7 43 13 41 11 42 7 42 11 41 7 42 10 4 4 8 4 30 10 ( ) ( ) 17 23 5 11 5 8 8 11 11 13 14 15 16 17 121 767 1,225 2.9 18.7 29.8 3.9

More information

ph

ph 14 12 9 3 4 1 7 1.1..................... 7 1.2 ph............................ 9 1.2.1...... 9 1.2.2.... 12 4.4..... 55 1.2.3 14 4.4.1......... 56 1.2.4............. 19 2 21 2.1.......... 21 2.2......................

More information

P.37 P.816 P.17 P.1819 contents 1 2

P.37 P.816 P.17 P.1819 contents 1 2 201211 NEW! P.37 P.816 P.17 P.1819 contents 1 2 3 4 5 6 7 8 http://www.tokiomarine-nichido.co.jp/ 1 2 16 3 11 4 1 18 9 10 5 6 11 12 18 9 10 6 7 8 13 1411 12 5 13 14 15 1615 16 21 17 18 0120-071-281 19

More information

-51-

-51- -50- -51- 11 3 28 8 1 24 7 2 36 10 1-52- -53- 1 2-54- 6 1 2 3 4 5 6 6 1 19 5 200 300ml 20 6 400ml -55- -56- 10-57- 4 2 20-58- 2,500-59- -60- -61- 2-62- 6 3-63- 9 68 1 6-64- 3-65- 4-66- 5 6-67- -68- 1 1

More information

- 2 -

- 2 - - 1 - - 2 - Table1-3 - - 4-1/2 Table2-5 - 2 3 3 Table2-6 - - 7-3.5 21 28 ( ) ( ) 1887( 20)7 ( ) 1987( 30) 140 YA-1( :125cc) 1954( 29) 8 1955( 30)7 3 1-8 - 20 1980 1980 YH 1-9 - 1-10 - 4 2 2 4 4 3 3 CI

More information

2006年3月8日

2006年3月8日 18 21 1990 2004 2 2005 14 15 2004 1990 2005 2003 300 7 2 1 2005 1972 100 40 6 1972 2004 197 6,500 2004 21 59 100 65 2007 5 2005 30 1.8 535.89 348.33 187.56 2006 2006 5 1 30 1 30 46 46 1 46 1000kl 4 1 100kl

More information

Microsoft Word - No.1武村.doc

Microsoft Word - No.1武村.doc 1) 1) 1) 2) 2) 2) 1) 2) 23 31.15% 23.1% () 2009 4 2011 8 65 ( ) ( ) 2 BMI (FIM ) 89 45 44 83.48 8.55 (p=0.66) 87.11 5.53 (p=0.39) 19 26 9 35 (P

More information

MRF 16 (1) 15 1 1 2 36 116 3 2 A A-2 15 2 (2) (3) 90 1 18 1 10 2 AA A-1 5% 5% 1% 18 5 25% 5 17 (1) 18 MRF 1 11 62 1 1 1 2 40 3 10 4 44 1 45 1 46 1 48 2 4 2 2 3 1 2 8 5 6 6 2 40 7 1 7 18 15 1 5 6 5 8 9

More information

日本呼吸器学会雑誌第48巻第6号

日本呼吸器学会雑誌第48巻第6号 Fig.1 Cutaneousfindingsandpathologicalfindingsofatransbronchiallungbiopsy(TBLB)andlichenifiedeczemaoftherightforearm.Thepatienthadlichenifiedeczemaonhisextremitiesandbodytrunk (1a:rightforearm,1b:leftthigh).Therewasinfiltrationoftheinflammatorylymphocytes,edemaandabrasioninthetype2alveolarepithelium

More information

取扱説明書 [F-08D]

取扱説明書 [F-08D] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 a bc d a b c d 17 a b cd e a b c d e 18 19 20 21 22 a c b d 23 24 a b c a b c d e f g a b j k l m n o p q r s t u v h i c d e w 25 d e f g h i j k l m n o p q r s

More information

29 IL-6 IL-6 PD PD MT PTOT PD Hoehn- Yahr 5 PT OT 40 5 MT MT UPDRS FIM CASMTCL FIM UPDRS 2 3 CAS MTCL MT PT OT PD

29 IL-6 IL-6 PD PD MT PTOT PD Hoehn- Yahr 5 PT OT 40 5 MT MT UPDRS FIM CASMTCL FIM UPDRS 2 3 CAS MTCL MT PT OT PD Jpn J Rehabil Med 2011 ; : 134.142 2010 9 11 IL- Myokine Myokine 1 IL 6 10 10 IL-6 40 20 40 60 IL-6 1.39 1.01 pg ml 20 2.23 1.71 pg ml 40 2.51 2.29 pg ml 60 0.63 0.59 pg ml 0.7 0.64 pg ml 0.72 0.55 pg

More information

Microsoft Word - 01マニュアル・入稿原稿p1-112.doc

Microsoft Word - 01マニュアル・入稿原稿p1-112.doc 4 54 55 56 ( ( 1994 1st stage 2nd stage 2012 57 / 58 365 46.6 120 365 40.4 120 13.0 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 4 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97

More information

取扱説明書 [F-05E]

取扱説明書 [F-05E] F-05E 12.11 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 a b 22 c d e 23 24 a o c d a b p q b o r s e f h i j k l m g f n a b c d e f g h 25 i j k l m n o p q r s a X b SD 26 27 28 X 29 a b c

More information

表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5

表 1 入院時検査所見 11,500L 471 L 17.0 gdl.3 L ph 7.49 PaCO 37.8 mmhg PaO 67.4 mmhg HCO 3.6 meql B E 1. meql 141 meql K 3.9 meql Cl 108 meql Ca 8.4 mgdl P 4.5 Ⅰ. 臨床編 A. 特殊な病態における輸液 1 新生児 未熟児における輸液 実践編症例検討 症例の経過と実際の輸液療法 症例 ❶ 0 主訴 分娩歴 38 4,110 g.4 SD 47.5 cm0.5 SD 3.5 cm0.5 SD 8 1 9 5 現病歴 35 mgdl 60 0 mgdl 入院時現症 150 50 37. 503 mmhg SpO 98FiO 0.1 入院時検査所見 33 mgdl

More information

untitled

untitled . B to C B to C EC 645 20 3,360 1,740 8,240 3,780 14,840 6,730 26,850 11,870 B to C 44,240 15,150 1. 2. 3. 4. 5. 6. 1. 2. 3. 4. 5. 1. 2. 3. ( Edy Mobile Edy Edy 20675050 179086.9 Edy

More information

untitled

untitled 21.0% 49.4% 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 The Transportation Planning of Takizawa () () () () () 46 ()

More information

342 1 42% 20% 90 2000 10 1 1 1 QOL 1) 4 2063 99 86.9 ADL A1 B2 IIIa M 1 5 QOL 2) QOL 3 QOL 59.4 3 73.1 23.1% QOL 3 QOL QOL 11 5 4 M 1 IV 1 1 IIIb 8 2

342 1 42% 20% 90 2000 10 1 1 1 QOL 1) 4 2063 99 86.9 ADL A1 B2 IIIa M 1 5 QOL 2) QOL 3 QOL 59.4 3 73.1 23.1% QOL 3 QOL QOL 11 5 4 M 1 IV 1 1 IIIb 8 2 2012 341 352 Psychotherapy in Medical Welfare 1 Tomohisa SASANO 2 1 701-0193 288 E-Mail: sasano@mw.kawasaki-m.ac.jp 341 342 1 42% 20% 90 2000 10 1 1 1 QOL 1) 4 2063 99 86.9 ADL A1 B2 IIIa M 1 5 QOL 2)

More information